PRX-102 (pegunigalsidase alfa)

BIOLOGICAL3 trials

Sponsors

Protalix

Conditions

Fabry Disease

Phase 1

Extension Study of PRX-102 for up to 60 Months

CompletedNCT01981720

ProtalixFabry Disease

Start: 2014-01-16End: 2021-11-09Updated: 2023-09-13

Phase 3

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

CompletedNCT02795676

ProtalixFabry Disease

Start: 2016-06-30End: 2022-07-31Updated: 2023-09-13

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

CompletedNCT03018730

ProtalixFabry Disease

Start: 2017-05-17End: 2020-01-09Updated: 2023-09-13

Related Papers

Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials.

2025-01-23

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

2024-05-2134 citations

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.

2023-10-2121 citations

MO034A SUBGROUP ANALYSIS OF FEMALE PATIENTS IN A PHASE 3 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PEGUNIGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE PREVIOUSLY TREATED WITH AGALSIDASE ALFA

Nephrology Dialysis Transplantation2021-05-01